Jefferies Highlights Positive HARMONi-2 Results for AKESO, Reaffirms Buy Rating with HK$226 Target

Stock News

Yesterday

Jefferies has released a research report indicating that AKESO (09926) achieved positive results from its HARMONi-2 study of Ivonescimab. The data showed that the interim overall survival (OS) analysis reached statistical significance, with the drug demonstrating a notable extension in OS compared to Pembrolizumab as a first-line monotherapy for PD-L1-positive non-small cell lung cancer.

The investment bank believes that Ivonescimab holds a distinct OS advantage, and the data is encouraging. Consequently, Jefferies maintains a "Buy" rating on AKESO with a target price of HK$226.

The data revealed that the median OS for the Ivonescimab group was 30.8 months, with a hazard ratio of 0.73 and a median follow-up of 36 months, whereas the Pembrolizumab group achieved a median OS of 22.6 months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1126314596"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126314596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126314596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126314596","market":"other","top_or_hot":-1,"title":"Jefferies Highlights Positive HARMONi-2 Results for AKESO, Reaffirms Buy Rating with HK$226 Target","media":"Stock News","content":"<p>Jefferies has released a research report indicating that <b>AKESO</b> (09926) achieved positive results from its HARMONi-2 study of Ivonescimab. The data showed that the interim overall survival (OS) analysis reached statistical significance, with the drug demonstrating a notable extension in OS compared to Pembrolizumab as a first-line monotherapy for PD-L1-positive non-small cell lung cancer.<br><br>The investment bank believes that Ivonescimab holds a distinct OS advantage, and the data is encouraging. Consequently, Jefferies maintains a \"Buy\" rating on <b>AKESO</b> with a target price of HK$226.<br><br>The data revealed that the median OS for the Ivonescimab group was 30.8 months, with a hazard ratio of 0.73 and a median follow-up of 36 months, whereas the Pembrolizumab group achieved a median OS of 22.6 months.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Highlights Positive HARMONi-2 Results for AKESO, Reaffirms Buy Rating with HK$226 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Highlights Positive HARMONi-2 Results for AKESO, Reaffirms Buy Rating with HK$226 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-15 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jefferies has released a research report indicating that <b>AKESO</b> (09926) achieved positive results from its HARMONi-2 study of Ivonescimab. The data showed that the interim overall survival (OS) analysis reached statistical significance, with the drug demonstrating a notable extension in OS compared to Pembrolizumab as a first-line monotherapy for PD-L1-positive non-small cell lung cancer.<br><br>The investment bank believes that Ivonescimab holds a distinct OS advantage, and the data is encouraging. Consequently, Jefferies maintains a \"Buy\" rating on <b>AKESO</b> with a target price of HK$226.<br><br>The data revealed that the median OS for the Ivonescimab group was 30.8 months, with a hazard ratio of 0.73 and a median follow-up of 36 months, whereas the Pembrolizumab group achieved a median OS of 22.6 months.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348827113.USD","symbol_name":"ALLIANZ RCM CHINA \"AT\" ACC","start_time":0,"source_url":"","article_id":"1126314596","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126314596","pubTimestamp":1789437625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jefferies has released a research report indicating that AKESO (09926) achieved positive results from its HARMONi-2 study of Ivonescimab. The data showed that the interim overall survival (OS)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","09926":"康方生物","BK1574":"生物医药B类股","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC"},"translate_title":"Jefferies 强调 AKESO HARMONi-2 的积极业绩，重申买入评级，目标为 226 港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":1,"09926":1},"content_text":"Jefferies has released a research report indicating that AKESO (09926) achieved positive results from its HARMONi-2 study of Ivonescimab. The data showed that the interim overall survival (OS) analysis reached statistical significance, with the drug demonstrating a notable extension in OS compared to Pembrolizumab as a first-line monotherapy for PD-L1-positive non-small cell lung cancer.The investment bank believes that Ivonescimab holds a distinct OS advantage, and the data is encouraging. Consequently, Jefferies maintains a \"Buy\" rating on AKESO with a target price of HK$226.The data revealed that the median OS for the Ivonescimab group was 30.8 months, with a hazard ratio of 0.73 and a median follow-up of 36 months, whereas the Pembrolizumab group achieved a median OS of 22.6 months.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}